SynthesisEuropean journal of clinical pharmacology2025
Safety and efficacy of fondaparinux use in hemodialysis patients with heparin-induced thrombocytopenia: a systematic review.
Synthesis in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeparin-induced thrombocytopenia (HIT) is a severe primary hypercoagulable disorder, particularly concerning in hemodialysis (HD) patients frequently exposed to heparin. Fondaparinux has emerged as a potential alternative anticoagulant, though supporting evidence is limited. This systematic review aimed to evaluate the safety and efficacy of fondaparinux in HD patients with HIT.
methodsWe searched PubMed/MEDLINE, Web of Science, Scopus, CENTRAL, ClinicalTrials.gov, and SCIndeks up to March 2, 2025. Eligible studies included clinical trials, observational studies, and case reports/series on fondaparinux use in adult HD patients with HIT. Data on demographics, clinical characteristics, diagnostics, dosing, administration routes, and outcomes were extracted and narratively synthesized.
resultsSeventeen studies with 37 patients (aged 38-88 years) were included. Dosing regimens and monitoring strategies varied widely across dialysis modalities, with the most common initial fondaparinux dose being 2.5 mg/day. Platelet recovery was observed in most cases. Bleeding occurred in 10.8% of patients, thrombotic events in 5.4%, and overall mortality was 16.2%. Vascular access thrombosis was reported in two patients (5.4%) following the initiation of fondaparinux. Some clotting of the extracorporeal circuit was reported during select sessions in 7 patients undergoing non-continuous dialysis modalities (18.9%), including five on high-flux HD, one on unspecified intermittent HD, and one on post-dilution hemodiafiltration.
conclusionsFondaparinux may be a potential alternative anticoagulant in HD patients with HIT, especially when first-line agents are unavailable. However, its use should be approached with caution and tailored to individual clinical circumstances, pending confirmation of its safety, efficacy, and optimal dosing and monitoring through larger prospective studies.
Indexed as
Identifiers
40925931What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.